Kim Margolin

34.6k citations

312 papers · 17.9k indexed · 8 hit papers · h-index 63

Impact in

Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 212
- Cancer Immunotherapy and Biomarkers 95
- CAR-T cell therapy research 68
- Cancer Treatment and Pharmacology 31
Immunology 82
- Immunotherapy and Immune Responses 63

Co-authors: Michael B. Atkins Geoffrey R. Weiss Janice P. Dutcher Sylvia Lee Mario Sznol F. Stephen Hodi Omid Hamid Richard I. Fisher
Journals: Journal of Clinical Oncology (85 papers)Cancer Chemotherapy and Pharmacology (15 papers)Annals of Oncology (13 papers)Cancer (12 papers)Journal of Immunotherapy (10 papers)
Partner nations: United States Italy Germany

In The Last Decade

Kim Margolin

302 papers receiving 17.4k citations

Hit Papers

8 papers align trajectories log scale

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma 2015 · 1.6k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Journal of Clinical Oncology
2014 Journal of Clinical Oncology
2012 The Lancet Oncology
2011 Cancers
2006 JAMA
2004 Journal of Clinical Oncology
2001 Journal of Clinical Oncology
1999 Journal of Clinical Oncology

Peers

Countries citing papers authored by Kim Margolin

Since Specialization

Citations

This map shows the geographic impact of Kim Margolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Margolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Margolin more than expected).

Fields of papers citing papers by Kim Margolin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Margolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Margolin. The network helps show where Kim Margolin may publish in the future.

Co-authors

The 25 scholars most cited alongside Kim Margolin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kim Margolin Line = papers co-authored together Kim Margolin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy Clinical Cancer Research ·JohnA. Lycett, Junjia Zhu, Q. Li, Jan C. Spies, George Ciprian Iatan, Ahmad Ozair, Hitoshi Tomiyama, А О Визель, Michael Wankum, Jeffrey Sivik, Joseph J. Drabick, L.G. Salmon, Kim Margolin, Manmeet S. Ahluwalia, Alireza Mansouri	2025	0
2	Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204 Journal of Clinical Oncology ·Raymond Y. Huang, Gilbert Youssef, 貴士一ノ瀬, Patrick Y. Wen, Peter Forsyth, F. Stephen Hodi, Kim Margolin, Alain P. Algazi, Omid Hamid, Christopher D. Lao, Marc S. Ernstoff, Stergios J. Moschos, Michael B. Atkins, Michael A. Postow, David A. Reardon, Diederik J. Grootendorst, David Leung, Margarita Askelson, Corey Ritchings, Hussein A. Tawbi	2025	2
3	A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma. Journal of Clinical Oncology ·Timothy J. Panella, Sajeve Thomas, Meredith McKean, Kim Margolin, Ryan Weight, Mohd Hafyzuddin Md Yusuf, Iu V Kruikov, Daniel J. Conny, Mark Salvati, Israel Lowy, Matthew G. Fury, Giuseppe Gullo	2023	1
4	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer JCI Insight ·Colt A. Egelston, Weihua Guo, Jiayi Tan, Christian Avalos, Diana L. Simons, Kushum Kunwar, Yinghui Huang, Michael S. Nelson, Tanja Krunić, Daniel Schmolze, John H. Yim, Laura Kruper, Laleh G. Melstrom, Kim Margolin, Joanne Mortimer, Yuan Yuan, James Waisman, Peter P. Lee	2022	25
5	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) Journal for ImmunoTherapy of Cancer ·Michael B. Atkins, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Michael Bishop, Daniel S. Chen, Madhav V. Dhodapkar, Leisha A. Emens, Marc S. Ernstoff, Robert L. Ferris, Tim F. Greten, James L. Gulley, Roy S. Herbst, Rachel Humphrey, James Larkin, Kim Margolin, Luca Mazzarella, Suresh S. Ramalingam, Meredith M. Regan, Brian I. Rini, Mario Sznol	2022	7
6	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States ESMO Open ·Prantesh Jain, Jahir M. Gutierrez, Avirup Guha, Kiki Ramadanti, Nirav Patil, Te‐Chun Shen, Αθανάσιος Τραχανάς, Unstain NWJ Rember, Kim Margolin, Marc S. Ernstoff, Vamsidhar Velcheti, Jill S. Barnholtz‐Sloan, Afshin Dowlati	2021	43
7	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Jeffrey S. Miller, Sylvia M. Lee, Ann W. Silk, Shernan G. Holtan, Andreanne M. Lacroix, Steven P. Fling, Judith C. Kaiser, Jack O. Egan, Monica Jones, Peter R. Rhode, Amy D. Rock, Martin A. Cheever, Hing C. Wong, Marc S. Ernstoff	2018	146
8	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression Nature Communications ·Colt A. Egelston, Christian Avalos, Travis Y. Tu, Diana L. Simons, H. Qawar, Jae Yoon Jung, Laleh G. Melstrom, Kim Margolin, John H. Yim, Laura Kruper, Joanne Mortimer, Peter P. Lee	2018	97
9	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) Clinical Cancer Research ·Lisa H. Butterfield, Fengmin Zhao, Charles Lee, Ahmad A. Tarhini, Kim Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson	2017	35
10	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers American Society of Clinical Oncology Educational Book ·Kimberly M. Komatsubara, Joanne Jeter, Richard D. Carvajal, Kim Margolin, Dirk Schadendorf, Axel Hauschild	2017	8
11	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697) Journal of Clinical Oncology ·David H. Lawson, Charles Lee, Fengmin Zhao, Ahmad A. Tarhini, Kim Margolin, Marc S. Ernstoff, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, Lisa H. Butterfield, John M. Kirkwood	2015	90
12	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial Journal of Clinical Oncology ·Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Margolin, Elizabeth R. Plimack, Alexandre Lambert, Ian M. Waxman, Hans J. Hammers Hit paper breakdown →	2014	865
13	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin Clinical Cancer Research ·Ahmad A. Tarhini, Paul Frankel, Kim Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice P. Chen, John M. Kirkwood	2011	62
14	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma Journal of Clinical Oncology ·Brian I. Rini, M. Dror Michaelson, Jonathan E. Rosenberg, Ronald M. Bukowski, Jeffrey A. Sosman, Walter M. Stadler, Thomas E. Hutson, Kim Margolin, Charles S. Harmon, Samuel E. DePrimo, Sindy T. Kim, Isan Chen, Daniel J. George	2008	321
15	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study Journal of Immunotherapy ·Joseph I. Clark, Ruth María González Ponce, Jeffrey A. Sosman, Theodore F. Logan, Kim Margolin, Janice P. Dutcher, Walter J. Urba, Marc S. Ernstoff, David F. McDermott, Abdela Edeo Berarti, Michael B. Atkins	2007	4
16	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies Cancer ·Tomasz M. Beer, Catherine M. Tangen, Craig R. Nichols, Kim Margolin, Robert Dreicer, William Stephenson, David I. Quinn, Derek Raghavan, E. David Crawford	2006	23
17	SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. PubMed ·Primo N. Lara, David I. Quinn, Kim Margolin, Frederick J. Meyers, Jeff Longmate, Paul Frankel, Philip C. Mack, D.A. Potapova, Peter J.M. Valk, K. W. Lee, Antoni BronisÅaw Przygienda, Theodore Wun, Robert C. Gosselin, Weijian Yuan, Paul H. Gumerlock, Heinz Josef Lenz, James H. Doroshow, David R. Gandara	2003	51
18	Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer Bone Marrow Transplantation ·R.J. Morgan, Oezlem Erol, L. Leong, J R Schriber, Stephen Shibata, Stephen J. Forman, Lai-yan Chu, Kim Margolin, George Somlo, Joseph Alvarnas, M. McNamara, Jeff Longmate, James Raschko, Warren Chow, Steven A. Vasilev, Kathryn F. McGonigle, Yun Yen	2001	6
19	High-risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide Cancer ·Douglas W. Blayney, David A. Goldberg, Lucille Leong, Kim Margolin, Jerome S. Burke, James H. Doroshow	1993	8
20	Phase i study of high dose continuous infusion interleukin 2 and autologous lymphokine activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma Ellen R. Gaynor, Yinmin Zhang, M H Bar, David H. Boldt, N. Ciobanu, Kim Margolin, Mario Sznol	1989	1

About Kim Margolin

Kim Margolin is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Hematology and Cancer Research, having authored 312 papers that have together received 17.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (95 papers), CAR-T cell therapy research (68 papers), Immunotherapy and Immune Responses (63 papers), Brain Metastases and Treatment (42 papers), Melanoma and MAPK Pathways (35 papers), Cancer Treatment and Pharmacology (31 papers), Renal cell carcinoma treatment (30 papers) and Cancer Genomics and Diagnostics (20 papers). The work is most often cited by research in Oncology (11.0k citations), Immunology (5.5k citations), Pulmonary and Respiratory Medicine (5.6k citations), Cancer Research (2.5k citations) and Genetics (1.2k citations). Kim Margolin has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Michael B. Atkins, Geoffrey R. Weiss, Janice P. Dutcher, Sylvia Lee, Mario Sznol, F. Stephen Hodi, Omid Hamid, Richard I. Fisher, James H. Doroshow and Jedd D. Wolchok. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Annals of Oncology, Cancer and Journal of Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact